Literature DB >> 1314777

Prognostic significance of histopathologic subtype and stage in small cell lung cancer.

A E Fraire1, E H Johnson, R Yesner, X B Zhang, H J Spjut, S D Greenberg.   

Abstract

A study of 149 light microscopic tissue slides from 147 patients with recorded initial diagnoses of small cell lung cancer (SCLC) (114 cases) and undifferentiated carcinoma (35 cases) was undertaken to test the reproducibility and prognostic impact of a new histopathologic subclassification of SCLC proposed by the Pathology Panel of the International Association for the Study of Lung Cancer (IASLC). This study was further designed to test the impact of clinical stage, age, sex, and race on survival. The tissue slides were blindly reclassified as SCLC or non-SCLC by a panel of five pathologists with no knowledge of the initial diagnosis. The SCLCs were divided into the three subtypes outlined by the IASLC pathology panel: small (classic or pure), mixed (small cell/large cell), and combined (small cell/squamous carcinoma or small cell/adenocarcinoma). Small cell lung cancer was clinically staged as local, regional, or distant. Consensus diagnosis (defined as agreement by at least three of the five pathologists) was achieved in 144 (96.6%) of the 149 cases. Of these 144 cases, 124 were reclassified as SCLC (115 [92.8%] small, five [4.0%] mixed, and four [3.2%] combined) and 20 were classified as non-SCLC. The median lengths of survival for the small, mixed, and combined subtypes were 225, 1,110, and 203 days, respectively (P = .025). Adequate staging data were available in 123 of the 124 SCLC cases. Of the 123 SCLC cases, 27 (21.9%) were local, 22 (17.9%) were regional, and 74 (60.2%) were distant stage. The median lengths of survival for the local, regional, and distant stages were 428, 251, and 111 days, respectively. This association was highly significant (P = .0001). We conclude that stage is the major determinant of survival in SCLC. Mixed subtypes had significantly longer survival times than the small or combined subtypes (P = .025). Survival times were longer for women than for men, and the survival time difference between men and women was significant (P = .0028). We found no significant differences in survival according to age or race.

Entities:  

Mesh:

Year:  1992        PMID: 1314777     DOI: 10.1016/0046-8177(92)90129-q

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

1.  Surgery for combined type small cell lung carcinoma.

Authors:  R Hage; J R Elbers; A Brutel de la Rivière; J M van den Bosch
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

2.  Expression and mutation of the c-kit gene and correlation with prognosis of small cell lung cancer.

Authors:  Hong-Yang Lu; Gu Zhang; Qiao-Yuan Cheng; Bo Chen; Ju-Fen Cai; Xiao-Jia Wang; Yi-Ping Zhang; Zeng Wang; Zhen-Yi Lu; Fa-Jun Xie; Wei-Min Mao
Journal:  Oncol Lett       Date:  2012-04-12       Impact factor: 2.967

3.  Role of pulmonary resection in the diagnosis and treatment of limited-stage small cell lung cancer: revision of clinical diagnosis based on findings of resected specimen and its influence on survival.

Authors:  Takashi Iwata; Noritoshi Nishiyama; Koshi Nagano; Nobuhiro Izumi; Shinjiro Mizuguchi; Takuma Tsukioka; Ryuhei Morita; Kyukwang Chung; Shoji Hanada; Kiyotoshi Inoue
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-01-13

4.  Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment.

Authors:  Hong-Yang Lu; Wei-Min Mao; Qiao-Yuan Cheng; Bo Chen; Ju-Fen Cai; Xiao-Jia Wang; Zeng Wang; Fa-Jun Xie
Journal:  Oncol Lett       Date:  2012-04-02       Impact factor: 2.967

Review 5.  Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors.

Authors:  Yi Shao; Dian-Sheng Zhong
Journal:  Int J Clin Oncol       Date:  2017-11-07       Impact factor: 3.402

6.  Genetics of a combined lung small cell carcinoma and large cell neuroendocrine carcinoma with adenocarcinoma.

Authors:  Giovanni Fellegara; Tiziana D'Adda; Francesco P Pilato; Elisabetta Froio; Luca Ampollini; Michele Rusca; Guido Rindi
Journal:  Virchows Arch       Date:  2008-06-13       Impact factor: 4.064

7.  Further understanding of an uncommon disease of combined small cell lung cancer: clinical features and prognostic factors of 114 cases.

Authors:  Yu Men; Zhouguang Hui; Jun Liang; Qinfu Feng; Dongfu Chen; Hongxing Zhang; Zefen Xiao; Zongmei Zhou; Weibo Yin; Luhua Wang
Journal:  Chin J Cancer Res       Date:  2016-10       Impact factor: 5.087

8.  [Clinical Analysis of 58 Patients with Small Cell Lung Cancer 
Combined with Squamous Cell Cancer].

Authors:  Yang Luo; Yu Men; Zhouguang Hui; Junling Li; Xuezhi Hao; Puyuan Xing
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-10-20

9.  Cytokinetic analysis of lung cancer by in vivo bromodeoxyuridine labelling.

Authors:  M M Tinnemans; B Schutte; M H Lenders; G P Ten Velde; F C Ramaekers; G H Blijham
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

10.  The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC).

Authors:  Yu Men; Yang Luo; Yirui Zhai; Jun Liang; Qinfu Feng; Dongfu Chen; Zefen Xiao; Zongmei Zhou; Zhouguang Hui; Luhua Wang
Journal:  Oncotarget       Date:  2017-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.